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Typhoid vaccine development with a human challenge model
Experimental human typhoid fever challenge was first 
described in 1896 by Wright, who vaccinated two men 
against typhoid fever and challenged one with what 
was then known as Salmonella typhosa.1 While challenge 
models are sometimes controversial, they offer enormous 
potential to study the pathogenesis of disease and to 
accelerate vaccine development, particularly in human-
restricted pathogens such as Salmonella enterica serovar 
Typhi. The Maryland typhoid human challenge model, 
which ran from 1952 to 1974, led to insights into typhoid 
fever and facilitated the development of live attenuated 
typhoid vaccine Ty21a.2,3 A 21st-century typhoid challenge 
model has been developed by the Oxford Vaccine Group.4
In The Lancet, Celina Jin and colleagues5 report results 
from challenging three groups of healthy adults from 
Oxford, UK, who were randomly assigned to receive 
Vi-conjugate vaccine, unconjugated Vi-polysaccharide 
vaccine, or control vaccine (ACYW135 meningococcal 
conjugate) with wild-type Quailes strain Salmonella Typhi. 
Results of this volunteer challenge have been awaited 
with much anticipation by the public health community 
interested in control of typhoid fever in endemic areas 
of south Asia and sub-Saharan Africa where S Typhi 
is increasingly antibiotic resistant and few treatment 
options remain. Vi-conjugate vaccines that have been 
in development represent a new instrument to help to 
control typhoid. The most advanced conjugate vaccine, 
Typbar-TCV (Vi-polysaccharide [Vi-PS] conjugated 
to tetanus toxoid, Vi-TT, Bharat Biotech, Hyderabad, 
India), is licensed in India where it has been shown to 
elicit robust serum Vi antibody responses after only one 
dose, even in Indian infants as young as 6 months.6 In 
toddlers, older children, and adults, Typbar-TCV was 
shown to be significantly more immunogenic than 
the unconjugated Bharat Vi-PS.6 Bharat Biotech has 
submitted an application to WHO for pre-qualification of 
their Vi-TT. If approved, this would allow the vaccine to 
be procured by UN agencies. However, despite evidence 
of safety and immunogenicity in Indian children and 
adults, heretofore, there has been no evidence of actual 
efficacy of the vaccine in diminishing the attack rate 
of typhoid fever upon exposure to virulent S Typhi 
compared with the control participants. Importantly, 
the authors provide the first data documenting that 
Typbar-TCV is protective.
112 participants were enrolled in this observer and 
participant-blinded, randomised controlled trial, which 
showed that the Vi-TT is well tolerated, achieved 100% 
seroconversion of Vi antibody (versus 89% for Vi-PS), 
and stimulated significantly higher geometric mean 
titres than did unconjugated Vi-PS. Most importantly, 
Jin and colleagues document that Vi-TT recipients 
had a significantly lower attack rate for the primary 
aim endpoint diagnosing typhoid fever than control 
recipients. With the primary endpoint used in this 
ambitious trial, the attack rate for typhoid diagnosis 
was 24 (77%) of 31 in control participants, 13 (35%) of 
37 in Vi-TT recipients, and 13 (35%) of 35 in those who 
received Vi-PS. This translates into vaccine efficacies 
of 54·6% (95% CI 26·8–71·8) for Vi-TT and 52·0% 
(23·2–70·0) for Vi-PS.
As the authors suggest, the field efficacy of Vi-TT 
vaccine might be higher; for example, a well designed 
and executed field trial of an unlicensed Vi-conjugate 
produced by the National Institutes of Health (Bethesda, 
MD, USA) in Vietnamese pre-school children showed 
an efficacy of 89% (95% CI 76–97) over 46 months of 
follow-up.7 One possible explanation lies in the primary 
endpoint of so-called typhoid infection used by Jin and 
colleagues5 (persistent fever ≥38°C for ≥12 h or S Typhi 
bacteraemia), which arguably is better suited to studying 
typhoid pathogenesis than assessing the efficacy of 
typhoid vaccines. Using slightly different endpoints 
such as fever 38oC or higher followed by a positive blood 
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culture, similar to surveillance in a field trial and to 
endpoints used in the Maryland challenge model, Jin and 
colleagues5 report that the efficacy of Vi-TT was 87·1% 
(95% CI 47·2–96·9), while efficacy of Vi-PS was 52·3% 
(–4·2 to 78·2). Although future typhoid challenges based 
on this as a co-primary endpoint would require larger 
sample sizes, the information gained might be more 
relevant and predictive of the efficacy that might be noted 
in a randomised controlled field trial. This highlights 
the need for the phase 3 and 4 trials, the first of which is 
expected to be initiated in Asia in late 2017 by the Typhoid 
Vaccine Acceleration Consortium (TyVAC), a partnership 
between the University of Maryland, the University of 
Oxford, and PATH funded by the Bill & Melinda Gates 
Foundation. However, because it will be some years 
before these field trials are reported, Jin and colleagues’ 
challenge study results are timely and engender optimism 
that an effective new instrument has become available to 
help to control typhoid in hyperendemic populations.
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